Novartis’ CAR-T therapy Kymriah hits endpoint in follicular lymphoma trial
Company expect to file regulatory submissions in 2021
Read Moreby Lucy Parsons | Aug 5, 2020 | News | 0
Company expect to file regulatory submissions in 2021
Read Moreby Selina McKee | May 14, 2020 | News | 0
The treatment could benefit 500 people with follicular lymphoma
Read Moreby Selina McKee | Sep 25, 2018 | News | 0
Verastem Oncology’s Copiktra has been approved in the US for the treatment relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma after at least two prior therapies.
Read Moreby Selina McKee | Sep 11, 2018 | News | 0
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Read Moreby Selina McKee | Sep 18, 2017 | News | 0
US regulators have issued an accelerated approval for Bayer’s relapsed follicular lymphoma therapy Aliqopa.
Read Moreby Selina McKee | Sep 18, 2017 | News | 0
The National Institute for Health and Care Excellence has turned down first-line use of Roche’s Gazyvaro in patients with untreated advanced follicular lymphoma on the NHS in England and Wales.
Read Moreby Selina McKee | Jul 26, 2017 | News | 0
The National Institute for Health and Care Excellence has issued final draft guidance recommending that use of Roche’s Gazyvaro to treat follicular lymphoma be funded for NHS use via the Cancer Drug Fund.
Read Moreby Selina McKee | Jun 16, 2016 | News | 0
Roche has won European approval for cancer drug Gazyvaro as a treatment for some patients with previously treated follicular lymphoma, the most common type of indolent non-Hodgkin’s lymphoma.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
